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Adeno-associated viral (AAV) vector-mediated gene replacement for the treatment of mus-
cular dystrophy represents a promising therapeutic strategy in modern medicine. One
major obstacle in using AAV vectors for in vivo gene delivery is the development of host
immune responses to the viral capsid protein and transgene products as evidenced in ani-
mal models and human trials for a range of genetic diseases. Here, we review immunity
against AAV vector and transgene in the context of gene delivery speciﬁc to muscles for
treating muscular dystrophies and non-muscle diseases in large animal models and human
trials, factors that inﬂuence the intensity of the immune responses, and immune modula-
tory strategies to prevent unwanted immune responses and induce tolerance to the vector
and therapeutic gene for a successful gene therapy.
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INTRODUCTION
Muscular dystrophies are a group of heterogeneous diseases that
primarily affect striated muscles throughout the body. Many of
these myopathies are caused by mutations in genes that encode
structural proteins which link the cytoskeleton of muscle ﬁbers
to the extracellular matrix. The absence of functional proteins
results in destabilization of the muscle membrane, increased mus-
cle fragility and degeneration, and progressive muscle wasting, all
of which compromise the patients’mobility and, in the severe dis-
ease forms (Emery, 2002) such as Duchenne muscular dystrophy
(DMD), lead to death.
Over the past decades, viral vector-mediated gene replacement
has evolved as an attractive treatment strategy. Studies focusing
on adenoviral (Ad), retroviral, and adeno-associated viral (AAV)
vectors have shown that delivery via these vectors of full-length
or truncated but functional genes improves the disease phenotype
in animal models (Gregorevic and Chamberlain, 2003; Dudley
et al., 2004; Gregorevic et al., 2004; Li et al., 2005; Liu et al.,
2005), which has led to initiation of early phase clinical trials
(Mendell et al., 2009, 2010a). However, a major obstacle iden-
tiﬁed from preclinical and clinical studies is the host immune
response to the viral capsid protein and the therapeutic trans-
gene product, which may limit the efﬁcacy or efﬁciency of this
approach.
This review will focus on recent reports of immunity to AAV
capsid proteins and transgene products in large animalmodels and
human trials of muscular dystrophy (summarized in the Table 1),
as well as strategies that are needed for a successful in vivo gene
transfer to muscle.
IMMUNITY TO AAV AND TRANSGENE WHEN DELIVERED TO
MUSCLE
INTRAMUSCULAR INJECTION OF AAV
Administration of AAV vectors to skeletal muscle via direct intra-
muscular injection has been the most common route utilized for
gene delivery while developing treatments for the muscular dys-
trophies. While fairly promising safety proﬁles were reported in
mouse models, cytotoxic T cell responses to AAV vector and trans-
gene product in muscle of large animal models have been reported
recently. In immunocompetent dogs, we reported that local intra-
muscular injection of AAV2 or AAV6 vectors in wild type or DMD
dogs induced robust T cell-mediated immune responses against
AAV capsid proteins that peaked 4weeks after vector injection and
eliminated much of the transgene expression by week 10 (Wang
et al., 2007a). The immune responses were triggered regardless
of the nature of the transgene delivered or the vector puriﬁca-
tion methods. Yuasa et al. (2007) reported that injection of AAV2
evoked strong inﬂammatory responses to transgene products in
dog muscles. Robust cellular inﬁltration was also reported by Yue
et al. (2008) when AAV9 vectors were injected into muscles of
normal adult dogs, but not in muscles of neonatal dogs.
The binding ability of AAV capsids to heparan sulfate proteo-
glycans (HSPG) was suggested to facilitate the uptake of certain
AAV serotypes, such as AAV2, by dendritic cells (DC), which leads
to antigenprocessing,MHCclass I antigenpresentation,anda con-
sequent cell-mediated cytotoxic T cell responses (Vandenberghe
et al., 2006). However, this notion has not been conﬁrmed in
large animal or humans. Studies by Takeda’s group (Ohshima
et al., 2009) demonstrated that cellular immune responses were
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Table 1 | Summary of studies using AAV gene transfer to muscle.
Disease model Species in
study
Transgene
product
Serotype
(route of injection)
Drugs (regimen) Immune
responses
Transgene
expression
DMD (Wang et al.,
2007a, 2010)
WT dogs cFIX, β-gal AAV1, 2, or AAV6
(IM)
None + <8weeks
DMD (Wang et al.,
2007b)
WT dogs cFIX AAV6 CSP/MMF
(8weeks)
− Sustained
DMD hu-μ-dys AAV6 CSP/MMF
(8weeks)
+ <12weeks
k9-μ-dys AAV6 ATG/CSP/MMF
(16weeks)
Limited >22weeks
DMD (Yuasa et al.,
2007)
WT dogs β-gal AAV2 (IM) None + <2weeks
β-gal AAV2 (IM) CSP (2weeks) + <2weeks
β-gal AAV2 (IM) CSP/MMF
(2weeks)
Reduced + >4weeks
DMD (Yue et al.,
2008)
WT dogs
(adult)
hu-PLAP AAV9 (IM) None + Limited at 8weeks
WT dogs
(neonatal)
hu-PLAP AAV9 (IM, i.v.) Limited >24weeks
DMD (Ohshima
et al., 2009)
WT dogs β-gal AAV2 or AAV8 (IM) None + <4weeks
WT dogs β-gal AAV8 (i.v.) Reduced + <8weeks
LGMD (Mendell
et al., 2009)
Human trial α-sarcoglycan AAV1 (IM) Prednisolone (days
0–2)
Limited 6weeks – 3 mos
LGMD (Mendell
et al., 2010b)
Human trial α-sarcoglycan AAV1 (IM) Prednisolone
before injection
+ in 1 out of 3 pts 6 mos for 2 out of 3
pts
LGMD (Herson
et al., 2011)
Human trial α-sarcoglycan AAV1 (IM) None Moderate + Limited expression
at week 4
DMD (Mendell
et al., 2010a)
Human mini-dys IM, but not speci-
ﬁed on serotype
Glucocorticoid prior
to and throughout
the study course;
prednisolone
before injection
+ in 4 out of 6 pts Not detectable
DMD (Gregorevic
et al., 2009)
WT dogs hu-PLAP AAV6 (i.v.) CSP/MMF
(6weeks)
+ Limited at week 6
hu-PLAP AAV6 (i.v.) Limited Much enhanced at
week 6
DMD (Kornegay
et al., 2010)
DMD(neonatal) hu-mini-dys AAV9 (i.v.) None + 16weeks for 2 out
of 4 dogs
DMD (Toromanoff
et al., 2008)
NHP rtTA, cmEpo AAV1 (IM, i.v.) AAV-LEA29Y (Belat-
acept, i.v.)
− Sustaining
rtTA, cmEpo AAV1 (IM, i.v.) AAV-LEA29Y (Belat-
acept, IM)
+
DMD (Rodino-
Klapac et al.,
2010)
NHP hu-u-dys AAV8 (IM, i.v.) None − 5 mos
HB (Herzog et al.,
1999)
Dogs cFIX AAV2 (IM) None + >17 mos
HB (Herzog et al.,
2001)
Dogs cFIX AAV2 (IM, i.v.) Cyclophosphamide
(6weeks)
± Sustained
HB (Haurigot
et al., 2010)
Dogs cFIX AAV2 or AAV6 (i.v.) Cyclophosphamide
(6weeks)
± 6 mos
HB (Wang et al.,
2005)
Dogs cFIX AAV8 (i.v.) None + 1−2 years
(Continued)
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Table 1 | Continued
Disease model Species in
study
Transgene
product
Serotype
(route of injection)
Drugs (regimen) Immune
responses
Transgene
expression
HB (Manno et al.,
2003)
Human trials hu-cFIX AAV2 (IM) None − 10 mos
LPL (Mingozzi
et al., 2009)
Human LPL AAV1 (IM) None + 6 mos
AAT (Brantly et al.,
2009)
Human AAT AAV1 (IM) None + ∼12 mos
AAT (Flotte et al.,
2011)
Human AAT AAV1 (IM) None + >3 mos
ATG, anti-thymocyte globulin; AAT, alpha-1 antitrypsin; β-gal, β-galactosidase; cFIX, canine factor IX; cmEpo, cynomolgus macaque erythropoietin; CSP, cyclosporine;
DMD, Duchenne muscular dystrophy; HB, hemophilia B; hu, human; IM, intramuscular; i.v., Intravascular; k9, canine; LGMD, limb-girdle muscular dystrophy; LPL,
lipoprotein lipase; MMF, mycophenolate mofetil; NHP, non-human primate; pts, patients; PLAP, placenta alkaline phosphates; rtTA, reverse tetracycline transactivator;
WT, wild type, +, positive for either humoral or cellular or both immune responses.; ±, limited humoral or cellular responses.
elicited in dog muscles transduced with either AAV2 or AAV8,
a non-HSPG binding serotype. The immune responses can be
induced by both the vector capsid protein and the transgene prod-
uct. Nevertheless, the authors documented less inﬂammation by
histological analysis following intramuscular injection of AAV8-
β-galactosidase compared to AAV2-β-galactosidase into dog mus-
cle, and AAV8-β-galactosidase expression did not last for more
than 4weeks (Ohshima et al., 2009). AAV1, another serotype that
does not bind HSPG, also induced signiﬁcant cellular immune
responses when injected into dog muscles (Wang et al., 2010).
In humans, a phase I clinical trial of limb-girdle muscular dys-
trophy (LMGD-2D; Mendell et al., 2009) reported both humoral
(in all three patients seen as early as 2 weeks) and cellular immu-
nity (in one patient detected from weeks 2 to 12) to AAV1
capsids following intramuscular injection of 3.25× 1011 vg/site,
though the immune response did not diminish transgene expres-
sion. However, the data are difﬁcult to interpret because of the
use of (1) a 3-day course of methylprednisolone (from day of
injection to day 2) in all patients; and (2) the extensor digito-
rum brevis muscle which is generally spared from the dystrophic
process, hence dose not display pre-existing and ongoing inﬂam-
mation, which is characteristic of dystrophic muscle. The use
of a muscle speciﬁc promoter may also contribute to the less-
ened immune responses. In a follow-up paper by Mendell et al.
(2010b), two out of three patients had sustained transgene expres-
sion at 6months, and humoral and T cell responses to AAV1 were
detected in the patient failed to show expression. Herson et al.
(2011) reported modest cellular inﬁltration at week 4 following
injection of 4.5× 1010 vg/site of AAV1, but not after a lower dose
of 3× 109 vg/site, into muscle of LGMD patients with transgene
expression being detected in limited muscle ﬁbers (4.7–10.5%).
A recent phase I trial on DMD from Mendell et al. (2010a) also
raised the potential of cellular immune responses to either self or
non-self dystrophin epitopes. In the study, AAV vectors carrying
a truncated but functional dystrophin gene were delivered intra-
muscularly into DMD patients. None of the patients displayed
mini-dystrophin gene expressing myoﬁbers at the two muscle
biopsy time points, days 42 and 90. Four out of six patients had
detectable dystrophin-speciﬁc T cells, including CD4+ and CD8+
T cells, in peripheral blood, with two patients having dystrophin-
speciﬁc T cells before vector treatment. In contrast, immune
responses to AAV capsid were not reported. The authors sug-
gested that T cells targeting self or non-self dystrophin epitopes
may have eliminated mini-dystrophin expressing muscle ﬁbers in
the study.
INTRAVASCULAR ADMINISTRATION OF AAV TO MUSCLES
Administration of AAV vectors to skeletal muscles via an intravas-
cular route is another strategy.Reports of immunity toAAVvectors
delivered intravascularly have not been consistent. Studies by Gre-
gorevic et al. (2009) documented marked inﬂammatory responses
in dog muscle following limb artery infusion; however, the use
of transient immunosuppression enhanced transgene expression.
Yue et al. (2008) did not observe similar immune responses fol-
lowing intra-jugular injection of AAV9 into neonatal dogs, and the
authors attributed this to the immature immune system in neona-
tal dogs. Following intravenous injection into neonatal dogs,AAV9
carrying a human mini-dystrophin, which is a potential antigen,
induced inﬂammatory responses detected by magnetic resonance
imaging at 8 weeks and by histological analysis of muscle samples
at 16weeks (Kornegay et al., 2010). Pelvic limb muscle atrophy
and contractures detected at 16weeks may be a result of the early
marked inﬂammation responses (Kornegay et al., 2010).
In non-human primates (NHP), both humoral and cellular
immunity were observed when AAV1 and AAV8 vectors were
delivered intramuscularly, but not with regional i.v. injection. The
immunity was not observed when animals were under immuno-
suppression with either mycophenolate mofetil plus prednisone
for 3weeks, or LEA29Y, a mutant of CTLA4-Ig which blocks cos-
timulatory signaling through CD28 pathway that is required for
optimal T cell activation (Toromanoff et al., 2008, 2010). Here,
LEA29Y was expressed from AAV vector delivered intravenously
to ensure therapeutic level. When LEA29Y was delivered intra-
muscularly, it did not eliminate immune responses to transgene
product. On the other hand, no cellular immunity was observed to
either AAV capsid or transgene following either intramuscular or
i.v. delivery to NHP muscle by Chicoine’s group (Rodino-Klapac
et al., 2010).
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ADMINISTRATION OF AAV TO MUSCLES OF NON-MUSCULAR
DYSTROPHIES
Muscle has also been a target for AAV-mediated gene transfer as
a potential means to deliver secreted gene products to the blood
for treating other genetic diseases due to easy access and muscle
tropism of some AAV serotypes. Muscles in these disease models
are normal comparing to the diseased muscle in muscular dys-
trophies. Immune responses to AAV viral capsid and/or transgene
products have been reported in some studies but not in the others.
Inmuscle-directed,AAV2-mediated canine factor IX (cFIX) trans-
fer for treating hemophilia B in dogs, while no cellular responses
were reported to either AAV2 capsid or cFIX, inhibitory anti-cFIX
antibodies were reported to develop in a dose–dependent manner
(Herzog et al., 1999, 2002). Transient immunosuppression with
cyclophosphamide prevented anti-cFIX antibody formation and
resulted in sustained transgene expression via either an intra-
muscular or intravascular delivery route (Herzog et al., 2001;
Arruda et al., 2005, 2010). In another study by Haurigot et al.
(2010), 6 weeks of immunosuppression with cyclophosphamide
did not prevent the development of anti-AAV antibody and T cell
inﬁltrates in muscle, and the T cells were transgene speciﬁc.
In human hemophilia B patients, AAV–FIX transfer to skele-
tal muscle did not result in therapeutic levels of FIX; however,
no immune responses were observed (Manno et al., 2003). T cell
responses to AAV1 capsid proteins were observed in a clinical trial
for lipoprotein lipase (LPL) deﬁciency (Mingozzi et al., 2009).
Speciﬁcally, AAV1 capsid-speciﬁc CD8+ T cells were detected at
4 weeks in half of the patients after intramuscular injection with
kinetics that is dose–dependent, while no T- or B-cell responses to
the LPL transgene product were seen. In a clinical trial for alpha-1
antitrypsin (AAT) deﬁciency (Brantly et al., 2009), humoral (by
day 14) and T cell (by day 14, responses to AAV1 capsid were
observed in all subjects though these immune responses did not
diminish the low level of transgene expression that was observed.
A recent phase II clinical trial by Flotte et al. (2011) further con-
ﬁrmed moderate to marked CD8+ T cell responses against AAV1
capsid protein following delivery of AAV1–AAT to muscles of
patients. AAT expression was sustained but declined after day 30,
and serum therapeutic AAT level was not achieved in any of the
patients receiving either 6× 1011, 1.9× 1012, or 6× 1012 vg/kg.
IMMUNE MODULATION
The ultimate goal of AAV-mediated gene therapy is to achieve
persistent transgene expression at therapeutic levels, however, at
present this goal is compromised by development of de novo or
ampliﬁcation of pre-existing humoral or cellular host immune
responses to both AAV capsid and transgene products. Preventive
strategies, such as use of alternative serotypes, changes in vector
dosing, route of administration, and fetal or neonatal administra-
tion may not be feasible or effective in many situations. Immune
modulation designed to prevent activation and proliferation of
antigen-speciﬁc T- and B-cells is more potent and may be required
in addition to non-immunosuppressive preventive strategies.
Studies using AAV-based therapy coupled with immunosup-
pression in muscular dystrophy are limited but encouraging. In a
dog model of DMD (Wang et al., 2007b), it was demonstrated that
a combination of cyclosporine (CSP), a calcineurin inhibitor that
impairs T cell activation; and mycophenolate mofetil (MMF), an
anti-metabolite that prevents proliferation of both T- and B-cells,
was able to prevent immune responses to AAV in muscles of nor-
mal dogs; in dystrophic muscle which contains pre-existing and
ongoing inﬂammation, a 5-day course of anti-thymocyte globulin
(ATG) was needed in addition to a 16-week course of CSP/MMF
to suppress immune responses to both AAV capsid and the canine
(k9) micro (μ)-dys transgene. More importantly, robust and pro-
longed expression of k9-μ-dys persisted for at least 22weeks after
withdrawal of all immunosuppression. Immunosuppression by
CSP and MMF also prevented cellular inﬁltration and led to
enhanced transgene expression following intravascular delivery
of AAV to muscle in dogs (Gregorevic et al., 2009). In human
patients, a short course of methylprednisolone was used with
LMGD and DMD (Mendell et al., 2009, 2010a), which lessened
cellular responses, however, there was no transgene expression.
The generation and maintenance of immunological memory
is critical for host protection when re-encountering a pathogen.
However, memory cells can be a barrier in viral-mediated
gene therapy for patients with muscular dystrophies who may
require multiple treatments with vectors throughout life. Despite
high transduction efﬁciency of AAV-mediated gene transfer, re-
administration of AAV vectors has resulted in little or no further
transduction events in tissues, such as skeletal muscle and lung.
This was correlated with the appearance of viral or transgene spe-
ciﬁc neutralizing antibodies (Halbert et al., 1997). Pre-existing
neutralizing antibodies or memory T cells speciﬁc to viral cap-
sid protein or transgene product were also suggested to prevent
sustained transgene expression in recent human trials (Kessler
et al., 1996; Xiao et al., 1996; Manno et al., 2006; Mingozzi
et al., 2007; Mendell et al., 2010a). However, a study on AAV
delivery into lung in mice (Halbert et al., 1998) demonstrated
that transient immunosuppression through blocking costimula-
tory signaling pathways with a combination of anti-CD40 ligand
antibody and CTLA4-Ig at the time of primary AAV exposure
allowed successful repeat administration of AAV to lung. More
recently,Arruda and Colleagues reported that the presence of neu-
tralizing antibodies to AAV2 did not prevent Intravascular AAV6
delivery to muscles of hemophilia B dogs given immunosuppres-
sion with cyclophosphamide 1 day prior to vector injection and
weekly thereafter for 6weeks (Herzog et al., 2001). Studies by the
Wilson’s group also showed sustained expression of factor IX car-
ried by AAV8 in AAV2-pretreated hemophilia dogs (Wang et al.,
2005).
CONCLUSION
Adeno-associated viral-mediated gene therapy for muscular dys-
trophies is a promising yet fairly complex therapeutic approach
under development for approximately 20 years. The advances in
the last two decades in the ﬁeld are remarkable and have energized
the planning and implementation of phase I clinical trials. Identi-
ﬁcation of immunity to AAV vectors emerged as a major challenge
from these studies and emphasizes the importance of appropriate
animal models to address safety and efﬁcacy of the approach and
predict clinical outcomes. Combining immunosuppressive ther-
apy with other preventive strategies may be necessary to induce
persistent antigen-speciﬁc tolerance in the gene therapy setting.
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